The Finnish patients who received sham surgery (and recovered) | Nudge Newsletter


Placebos And Marketing

Read online


From December 2007 to January 2012, 146 men participated in an eye-opening study¹.

All men had persistent knee pain.

All had visited public hospitals in Finland and asked for help.

Here's where the study started.

Half underwent arthroscopic partial meniscectomy (removal of damaged meniscus tissue). That's the appropriate treatment.

The other half underwent sham surgery (anaesthesia and incisions but no tissue removed). It was a placebo surgery.

The sham group believed they'd had tissue removed, even though they hadn't.

So, what happened?

After 12 months, there was no difference between those who had real surgery and those who only thought they had surgery.

Both had the same amount of reduced pain.

Five years later, researchers followed up and found the same result.

The placebo group recovered 1) at the same rate, and 2) to the same degree.

The expectation of treatment was as effective as the treatment itself.

Is marketing a placebo?

That fake surgery is a type of marketing.

It built expectations around the service, which influenced the perceptions.

Similarly, Anton de Craen² reviewed 12 studies and found red painkillers are perceived as more potent than white ones.

The two painkillers are the same, but the colouring influences perception.

Despite this, only 14% of painkillers in pharmacies are red.

We assume customers are rational.

We think there's no way a headache can be cured by colouring.

But the sham surgery proves that's not true. Marketing alters our perception.

My point is, if Finnish blokes can psychically recover from knee pain with a sham surgery, imagine how good marketing could change how people enjoy you: food, software, guitar lessons, art, pottery, conference talks, etc.

What do you think? — Phill

P.S. Thanks to Gareth Harvey for sharing this study on LinkedIn.

¹Sihvonen, R., Paavola, M., Malmivaara, A., Itälä, A., Joukainen, A., Kalske, J., Nurmi, H., Kumm, J., Sillanpää, N., Kiekara, T., Turkiewicz, A., Toivonen, P., Englund, M., Taimela, S., & Järvinen, T. (2013). Arthroscopic partial meniscectomy for a degenerative meniscus tear: A 5-year follow-up of the placebo-surgery controlled FIDELITY (Finnish Degenerative Meniscus Lesion Study) trial. British Journal of Sports Medicine.

²Shotton, R. (2018). The choice factory: 25 behavioural biases that influence what we buy. London: Harriman House.

As a behavioural science practitioner, I believe in the peak-end rule*

Tune into Nudge | Advertise with Nudge | Unsubscribe

Nudge Newsletter

I spend 18 hours each week turning marketing psychology into readable newsletters.

Read more from Nudge Newsletter

Differential Price Framing Read online Want people to go premium? Don’t show them the full price. Show them the difference. That’s the idea behind differential price framing. In 2019, David Hardisty¹ at UBC tested it with New York Times subscriptions. Group A saw this: – $9.99/month for web + app – $16.99/month for web, app, print, podcast, crossword Group B saw this: – $9.99/month for web + app – +$7/month for all the extras Same total price. Different framing. But in Group B, twice as many...

Veblen Effect Read online Last week, I wrote about how Blue-Emu successfully sells pain relief cream (that doesn't actually cure pain). It indicated that perception trumps reality and reminded me of this study 👇 Rory Sutherland described this eloquently in a recent talk, saying: “I don’t have a $0.79 headache—I’ve got a $3.99 headache!” It's not just painkillers that benefit from higher prices. Eco-products do too. Research¹ cited in the brilliant Science Says measured sales of sustainable...

Operational Transparency Read online Voltarol is the world's number one pain relief gel. Unlike almost every other gel on the market, Voltarol actually works. Clinical tests have been done to prove that the gel penetrates the skin to supply pain relief. And yet, there are dozens of other very successful paom relief creams that don't supply real pain relief. Take Blue-Emu, an over-the-counter cream with $42 million in annual sales. So, why is Blue-Emu successful in a world where Voltarol...